Clinical trials: Safety Study, active
Breast Cancer Female
Time Restricted Eating During Chemotherapy for Breast Cancer
Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment.
- Trial name
- NCT05259410
- Testing
- TRE, MedTRE
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Septic Shock, Methylene Blue
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the…
- Conditions
- Septic Shock, Methylene Blue, Sepsis
- Trial name
- NCT06481410
- Testing
- Methylene Blue Intervention Group, Normal Saline Control Group
- Where
- China
- Volunteers
- 488 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Plaque Psoriasis
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
- Trial name
- NCT06630559
- Testing
- CT-P55, EU-approved Cosentyx
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Celltrion
Prion Disease
PrP-targeting siRNA Safety & Mechanism Study
The purpose of this trial is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic impact of PrP-siRNA in symptomatic prion disease patients and in pre-symptomatic adults at genetic risk for prion disease.
- Trial name
- PRiSM (NCT07444580)
- Testing
- PrP-siRNA
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Broad Institute of MIT and Harvard
Leukemia, Leukemia, Myeloid
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
This single-center prospective cohort study aims to evaluate the efficacy and safety of Intensifying treatment with Venetoclax along with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) except…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Trial name
- NCT06643962
- Testing
- Venetoclax, Idarubincin, Cytarabine
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Affiliated Hospital of Nantong University
Differentiated Thyroid Cancer
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer.
- Trial name
- METATHYRAF (NCT03416686)
- Testing
- Radiofrequency (RF star electrode electrode_Fixed)
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myositis, Active Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA+ (NCT05979441)
- Testing
- Efgartigimod PH20 SC
- Where
- 92 sites in United States, Argentina and 27 more
- Volunteers
- 240 people
- Sponsor
- argenx
Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication
Red Blood Cell Transfusion in ECMO - A Feasibility Trial
Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe…
- Conditions
- Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication, Disability Physical, Cognitive Ability, General
- Trial name
- ROSETTA (NCT05814094)
- Testing
- Red Blood Cell Transfusion
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Healthy
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects
The primary study objective is to evaluate the safety and tolerability of XQ-001 for inhalation after single and multiple nebulized inhalation administration in healthy Chinese adult subjects.
- Trial name
- NCT06918366
- Testing
- Part A - single rising dose 1, Part A - single rising dose 2, Part A - single rising dose 3
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Brilliant Inspiration Biotherapeutics
Netherton Syndrome
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
- Trial name
- NCT05789056
- Testing
- QRX003, 4% Lotion
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Quoin Pharmaceuticals
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT07235202
- Testing
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel
- Where
- 4 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Advanced Solid Tumors
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
This is an open-label, multicenter, Phase Ib/II clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of FL115 in combination with the anti-PD-1 monoclonal…
- Trial name
- NCT07131202
- Testing
- FL115+PD-1
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Idiopathic Recurrent Pericarditis
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068.
- Trial name
- NCT05673902
- Testing
- RPH-104
- Where
- Russia
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Hypertension
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.
- Trial name
- NCT07748702
- Testing
- CKD-339, D311, D107
- Where
- South Korea
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Locally Advanced Solid Tumor
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06658353
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Invasive Fungal Infection
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants <2 years of age with invasive fungal infection…
- Trial name
- NCT04665037
- Testing
- Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease
Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
This is a prospective, randomized, open-label, parallel-controlled clinical trial to evaluate the efficacy and safety of targeted IL-17A inhibition with secukinumab on cardiovascular and renal endpoints in 100 patients with…
- Conditions
- Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery Disease
- Trial name
- NCT07704190
- Testing
- Secukinumab (75 mg), Standard Medical Therapy
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
HIV, HIV Infection
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day.
- Trial name
- Codivir® (NCT06676410)
- Testing
- ICF, Eligibility Assessment, Demographic data
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Code Pharma
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Safety and Efficacy of OTL78
This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an…
- Trial name
- NCT07725523
- Testing
- 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Clinton Bahler
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.